Leucid Bio Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $9.3M

  • Investors
  • 7

Leucid Bio General Information

Description

Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatment options. The company specializes in the development of chimeric antigen receptor (CAR) T-cell therapies that produce a durable response than previous CAR T generations, enabling healthcare professionals to improve treatment outcomes and save the lives of patients with refractory cancers.

Contact Information

Website
www.leucid.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor
  • Bermondsey Wing Guys Hospital
  • London SE1 9RT
  • England, United Kingdom
+44 01234
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3rd Floor
  • Bermondsey Wing Guys Hospital
  • London SE1 9RT
  • England, United Kingdom
+44 01234

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Leucid Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A1) 01-Feb-2025 $9.3M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 21-Oct-2021 Completed Clinical Trials - Phase 2
3. Later Stage VC 19-Dec-2019 Completed Clinical Trials - Phase 1
2. Early Stage VC 04-Jul-2017 $2.88M $2.88M Completed Clinical Trials - Phase 1
1. University Spin-Out 27-Nov-2014 Completed Clinical Trials - Phase 1
To view Leucid Bio’s complete valuation and funding history, request access »

Leucid Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 Preferred
Series A1 Preferred
Series A Preferred
Series A Preferred
Series A Preferred 1,714,228 $0.001235 $3.66 $3.66 1x $3.66 8.99%
Seed Preference 4,250,000 $0.001235 $1.23 $1.23 1x $1.23 22.29%
To view Leucid Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Leucid Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatm
Drug Discovery
London, United Kingdom
19 As of 2026

London, United Kingdom
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Leucid Bio Competitors (3)

One of Leucid Bio’s 3 competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Autolus Formerly VC-backed London, United Kingdom
Cellectis Formerly VC-backed Paris, France
Celyad Oncology Formerly VC-backed Mont-Saint-Guibert, Belgium
You’re viewing 3 of 3 competitors. Get the full list »

Leucid Bio Patents

Leucid Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025196207-A1 Compositions and methods for use in depleting senescent cells and treating aging Pending 20-Mar-2024
GB-202403716-D0 Parallel chimeric antigen receptors (pcars) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof Inactive 14-Mar-2024
GB-202403717-D0 Therapeutic agents Inactive 14-Mar-2024
GB-202403718-D0 Therapeutic agents Inactive 14-Mar-2024
GB-202403720-D0 Therapeutic agents Inactive 14-Mar-2024
To view Leucid Bio’s complete patent history, request access »

Leucid Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Leucid Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
2invest Corporation Minority
4basebio Corporation Minority
British Business Bank Lender/Debt Provider Minority
Vulpes Investment Management Family Office Minority
Epidarex Capital Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Leucid Bio FAQs

  • When was Leucid Bio founded?

    Leucid Bio was founded in 2014.

  • Where is Leucid Bio headquartered?

    Leucid Bio is headquartered in London, United Kingdom.

  • What is the size of Leucid Bio?

    Leucid Bio has 19 total employees.

  • What industry is Leucid Bio in?

    Leucid Bio’s primary industry is Drug Discovery.

  • Is Leucid Bio a private or public company?

    Leucid Bio is a Private company.

  • What is the current valuation of Leucid Bio?

    The current valuation of Leucid Bio is .

  • What is Leucid Bio’s current revenue?

    The current revenue for Leucid Bio is .

  • How much funding has Leucid Bio raised over time?

    Leucid Bio has raised $30.6M.

  • Who are Leucid Bio’s investors?

    2invest, 4basebio, British Business Bank, Vulpes Investment Management, and Epidarex Capital are 5 of 7 investors who have invested in Leucid Bio.

  • Who are Leucid Bio’s competitors?

    Autolus, Cellectis, and Celyad Oncology are competitors of Leucid Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process